Blog Archives - Page 4 of 11 - Myriad RBM
  • Subscribe to our Blog

    Receive excerpts from our latest posts via email.

  • Categories


    Researchers Identify Signature Protein Biomarkers for Predicting Severity in Flu Cases

    Investigators observed samples from 84 naturally influenza-infected individuals and found increased levels of cytokines MCP-3, IFNa2 and plasma IL-10 predicted progression to more severe flu symptoms. While increased levels of plasma IL-10, MCP-3 and IL-6 levels predicted hospitalization. The findings from this paper also explain why infants are at high risk for complications, and why […]

    » Read this post

    A Digest of the Utility of Inflammatory Biomarkers in Major Depression

    A comprehensive synopsis from Murdoch University reviews the current state of peripheral inflammatory biomarkers and their potential to improve the treatment and diagnosis of major depression.

    » Read this post

    Examining the role inflammatory biomarkers play in an upcoming COPD study

      This paper outlines the protocol for a clinical study aimed at determining whether roflumilast (a lon-acting inhibitor of the PDE-4 enzyme) can reduce the inflammation present in patients with moderate-to-severe COPD. As part of the study, biomarkers will be used to quantify the effect that roflumilast has on both systemic and pulmonary inflammation. Previous […]

    » Read this post

    Identifying Prognostic Biomarkers for Amyotrophic Lateral Sclerosis

    Using multiplex biomarker analysis, researchers at Penn State University aim to define a panel of prognostic ALS markers.  This study shows the most meaningful results were obtained when combining biomarkers from CSF and plasma, rather than focusing on a single parameter. The combined plasma and CSF panel consists of six markers and accurately predicted the […]

    » Read this post

    Recorded Webinar: Quantitative Profiling of the Intrinsic Pathway of Apoptosis in Tumor Tissue using Myriad RBM’s Multiplex ApoptosisMAP™

    If you were unable to attend the webinar or would like to view the webinar again, a recorded version is now available for your convenience. View Recorded Webinar Learn about the creation of Myriad RBM’s fully validated, quantitative ApoptosisMAP and its application in cancer therapy research. The webinar highlights the main features of the service, […]

    » Read this post

    Using Renal Biomarkers to Advance Drug and Diagnostic Development in Kidney Disease

    Read this ebook, published by FierceBiotech, to learn how researchers are using new, more sensitive biomarkers to develop drugs and diagnostics in kidney disease.

    » Read this post

    The Need for Additional Translational Biomarkers

    The authors of this paper review the various methods of safety biomarker discovery and development, and challenge researchers to advance the use of safety biomarkers that are indicative of drug-induced toxicity. This type of research typically spans both preclinical and clinical development programs. Having the ability to identify translational safety biomarkers on the same technology […]

    » Read this post

    Blood-based Biomarkers of Alzheimer’s disease

    As we continue to develop a better understanding of the underlying biology for neurological diseases such as Alzheimer’s, researchers are seeking biomarkers that may help in numerous ways. From early diagnosis or disease progression, to surrogate efficacy markers for treatments, biomarkers may be the key to better studying these diseases. The challenge is determining which […]

    » Read this post

    Cancer Biomarkers – Historically undervalued but it’s time for a change

    Tumor-Biomarker Diagnostics: More and more experts are realizing the value of biomarkers in cancer research, not only to monitor tumor progression, but also to guide the treatment of patients.  Understanding these factors has the potential to save tremendous amounts of money for researchers in clinical trials and could even influence insurance reimbursement plans for those […]

    » Read this post

    Markers of Neurodegeneration in Multiple Sclerosis

    A recent study has identified the increased presence of neurofilament subunits (NFL) in the serum and cerebrospinal fluid of patients with multiple sclerosis (MS). The research, published in the Journal of Neuroimmunology, suggests that NFL may induce an immune response and represent and early marker of axonal damage. The results support many previous findings that […]

    » Read this post